{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:12:24Z","timestamp":1790248344404,"version":"4.1.0"},"reference-count":142,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015471","name":"Mater Foundation","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100015471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003463","name":"Haematology Society of Australia and New Zealand","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100003463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000926","name":"Leukaemia Foundation","doi-asserted-by":"publisher","award":["PhD scholarship"],"award-info":[{"award-number":["PhD scholarship"]}],"id":[{"id":"10.13039\/501100000926","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1142980"],"award-info":[{"award-number":["APP1142980"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. Advanced stage disease is considered incurable and is characterized by a prolonged relapsing\/remitting course. A significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. Recent advances in our understanding of the unique genetic and immune biology of FL have led to increasingly potent and precise novel targeted agents, suggesting that a chemotherapy-future may one day be attainable. The current pipeline of new therapeutics is unprecedented. Particularly exciting is that many agents have non-overlapping modes of action, offering potential new combinatorial options and synergies. This review provides up-to-date clinical and mechanistic data on these new therapeutics. Ongoing dedicated attention to basic, translational and clinical research will provide further clarity as to when and how to best use these agents, to improve efficacy without eliciting unnecessary toxicity.<\/jats:p>","DOI":"10.3390\/jpm11020152","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T14:23:27Z","timestamp":1614003807000},"page":"152","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeted Treatment of Follicular Lymphoma"],"prefix":"10.3390","volume":"11","author":[{"given":"Karthik","family":"Nath","sequence":"first","affiliation":[{"name":"Mater Research Institute, University of Queensland, Brisbane, QLD 4101, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher K.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Mater Research Institute, University of Queensland, Brisbane, QLD 4101, Australia"},{"name":"Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Magnano","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Roy","year":"2004","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: A retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tobin, J.W.D., Keane, C., Gunawardana, J., Mollee, P., Birch, S., Hoang, T., Lee, J., Li, L., Huang, L., and Murigneux, V. (2019). Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated with Reduced Intratumoral Immune Infiltration. J. Clin. Oncol.","DOI":"10.1200\/JCO.18.02365"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: A phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as Treatment for Patients with Relapsed\/Refractory Follicular Lymphoma: Results from the Open-Label, Multicenter, Phase II DAWN Study","volume":"36","author":"Gopal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjh.16424","article-title":"The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma","volume":"189","author":"Fowler","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1200\/JCO.2018.36.15_suppl.7549","article-title":"Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL)","volume":"36","author":"Fowler","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients with Refractory Indolent Non-Hodgkin Lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.15552","article-title":"An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma","volume":"184","author":"Andorsky","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2019-124231","article-title":"Rapid and Durable Responses with the SYK\/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed\/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab","volume":"134","author":"Smith","year":"2019","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/blood-2019-129422","article-title":"Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)","volume":"134","author":"Nastoupil","year":"2019","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood-2018-99-114409","article-title":"Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_25","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs. bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2020.38.15_suppl.8008","article-title":"Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL)","volume":"38","author":"Jacobson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-138983","article-title":"Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed\/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial","volume":"136","author":"Fowler","year":"2020","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-135839","article-title":"Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial","volume":"136","author":"Assouline","year":"2020","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136044","article-title":"Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: Final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Armand, P., Janssens, A.M.H., Gritti, G., Radford, J., Timmerman, J.M., Pinto, A., Mercadal Vilchez, S., Johnson, P.W.M., Cunningham, D., and Leonard, J.P. (2020). Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma. Blood.","DOI":"10.1182\/blood.2019004753"},{"key":"ref_34","first-page":"414","article-title":"High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study","volume":"130","author":"Nastoupil","year":"2017","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood.V99.7.2562","article-title":"Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma","volume":"99","author":"Zhu","year":"2002","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/blood-2015-04-640912","article-title":"DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma","volume":"126","author":"Amin","year":"2015","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2141.2003.04086.x","article-title":"Follicular lymphoma lacking the t(14;18)(q32;q21): Identification of two disease subtypes","volume":"120","author":"Horsman","year":"2003","journal-title":"Br. J. Haematol"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"32650","DOI":"10.1074\/jbc.M806340200","article-title":"Molecular mechanism of the Syk activation switch","volume":"283","author":"Tsang","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2006-02-003921","article-title":"Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells","volume":"108","author":"Irish","year":"2006","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/leu.2011.301","article-title":"Characterization of intratumoral follicular helper T cells in follicular lymphoma: Role in the survival of malignant B cells","volume":"26","author":"Yssel","year":"2012","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/jpet.114.218164","article-title":"The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","article-title":"Targeting the B cell receptor pathway in non-Hodgkin lymphoma","volume":"27","author":"Valla","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11877","DOI":"10.1074\/jbc.M010512200","article-title":"CARD11 and CARD14 are novel caspase recruitment domain (CARD)\/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B","volume":"276","author":"Bertin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/hon.2440_12","article-title":"Phase 3 study of ibrutinib in combination with rituximab versus placebo in combination with rituximab in patients with treatment-na\u00efve follicular lymphoma (perspective)","volume":"35","author":"Rule","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"TPS8601","DOI":"10.1200\/jco.2015.33.15_suppl.tps8601","article-title":"A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma","volume":"33","author":"Fowler","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2020-141672","article-title":"Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing in Situ Vaccination","volume":"136","author":"Shree","year":"2020","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-141377","article-title":"Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma","volume":"136","author":"Shree","year":"2020","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: An open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2019.37.15_suppl.7512","article-title":"Results of the PI3K\u03b4 inhibitor ME-401 alone or with rituximab in relapsed\/refractory (R\/R) follicular lymphoma (FL)","volume":"37","author":"Zelenetz","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3324\/haematol.2017.169656","article-title":"Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"102","author":"Anas","year":"2017","journal-title":"Haematologica"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/ajh.25634","article-title":"Combination trial of duvelisib (IPI-145) with rituximab or bendamustine\/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia","volume":"94","author":"Flinn","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"513702","DOI":"10.1155\/2012\/513702","article-title":"Molecular action of lenalidomide in lymphocytes and hematologic malignancies","volume":"2012","author":"McDaniel","year":"2012","journal-title":"Adv. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: Implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Reddy","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/hon.75_2629","article-title":"Augment phase iii study: Lenalidomide\/rituximab (r2) improved efficacy over rituximab\/placebo in relapsed\/refractory follicular patients irrespective of pod24 status","volume":"37","author":"Leonard","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_68","unstructured":"National Cancer Institute (2021, February 17). Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT02568553."},{"key":"ref_69","unstructured":"M.D.Anderson Cancer Center, and National Cancer Institute (2021, February 17). Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients with Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT02446457."},{"key":"ref_70","unstructured":"M.D.Anderson Cancer Center, and National Cancer Institute (2021, February 17). Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04404088."},{"key":"ref_71","unstructured":"Peter MacCallum Cancer Centre (2021, February 17). Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients with Treatment-Na\u00efve Follicular Lymphoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03980171."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/blood-2016-06-718106","article-title":"Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103","volume":"128","author":"Ujjani","year":"2016","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2352-3026(17)30028-5","article-title":"Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: The Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials","volume":"4","author":"Smith","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-134949","article-title":"Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and\/or Refractory B-Cell Non-Hodgkin Lymphoma","volume":"136","author":"Michot","year":"2020","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"Bodor","year":"2013","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","article-title":"Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response","volume":"37","author":"Beguelin","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-137245","article-title":"Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response","volume":"136","author":"Salles","year":"2020","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-136653","article-title":"A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma","volume":"136","author":"Patel","year":"2020","journal-title":"Blood"},{"key":"ref_80","unstructured":"(2021, February 17). Study in Subjects with Relapsed\/Refractory Follicular Lymphoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04224493."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1038\/bcj.2017.32","article-title":"EZH2 alterations in follicular lymphoma: Biological and clinical correlations","volume":"7","author":"Huet","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137772","article-title":"Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed\/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials","volume":"136","author":"Proudman","year":"2020","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A Phase I\/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed\/Refractory Lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood.2020008194","article-title":"BCL-2 inhibition in follicular lymphoma: Can we tip the scales?","volume":"136","author":"Fowler","year":"2020","journal-title":"Blood"},{"key":"ref_88","unstructured":"PrECOG, LLC, and Genentech, Inc. (2021, February 17). Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03113422."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.1038\/s41467-020-19672-2","article-title":"Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9","volume":"11","author":"Liu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","article-title":"Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells","volume":"167","author":"Boice","year":"2016","journal-title":"Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2020.38.15_suppl.8001","article-title":"Phase I Alexander study of AUTO3, the first CD19\/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed\/refractory (r\/r) DLBCL","volume":"38","author":"Osborne","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Abel, A.M., Yang, C., Thakar, M.S., and Malarkannan, S. (2018). Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01869"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: The emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13287-020-01741-4","article-title":"Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies","volume":"11","author":"Shankar","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_103","unstructured":"M.D.Anderson Cancer Center (2021, February 17). Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03056339."},{"key":"ref_104","unstructured":"Dana-Farber Cancer Institute (2021, February 17). A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03361852."},{"key":"ref_105","unstructured":"XEME Biopharma Inc. (2021, February 17). Oncoquest-L Vaccine in Patients with Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT02194751."},{"key":"ref_106","unstructured":"Washington University School of Medicine (2021, February 17). Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients with Follicular Lymphoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03121677."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/14712598.2011.572874","article-title":"Bispecific antibodies engage T cells for antitumor immunotherapy","volume":"11","author":"Choi","year":"2011","journal-title":"Expert Opin. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2019-122451","article-title":"Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed\/Refractory (R\/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)","volume":"134","author":"Bannerji","year":"2019","journal-title":"Blood"},{"key":"ref_110","unstructured":"(2021, February 17). Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03888105."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-136571","article-title":"Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed\/Refractory B Cell Lymphoma","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2018.36.15_suppl.7507","article-title":"Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed\/refractory (r\/r) FL and DLBCL","volume":"36","author":"Sehn","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2019-123669","article-title":"Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed\/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib\/II Trial","volume":"134","author":"Diefenbach","year":"2019","journal-title":"Blood"},{"key":"ref_115","unstructured":"(2021, February 17). A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL), Available online: https:\/\/ClinicalTrials.gov\/show\/NCT02611323."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"61425","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1158\/1078-0432.CCR-20-0558","article-title":"TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti\u2013PD-1 Response in Follicular Lymphoma","volume":"26","author":"Yang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-141462","article-title":"Identification of LAG3+ T Cell Populations in the Tumor Microenvironment of Classical Hodgkin Lymphoma and B-Cell Non-Hodgkin Lymphoma","volume":"136","author":"Takata","year":"2020","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2019-130050","article-title":"Intra-Tumoral CD8+ T-Cells in Follicular Lymphoma Contain Large Clonal Expansions That Are Amenable to Dual-Checkpoint Blockade","volume":"134","author":"Nath","year":"2019","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2019-127474","article-title":"Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"ref_124","first-page":"481","article-title":"Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis","volume":"130","author":"Younes","year":"2017","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat. Med."},{"key":"ref_127","unstructured":"(2021, February 17). Trial of Magrolimab (Hu5F9-G4) in Combination with Rituximab or Rituximab + Chemotherapy in Participants with Relapsed\/Refractory B-cell Non-Hodgkin\u2019s Lymphoma, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT02953509."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1038\/s41375-020-0811-3","article-title":"Targeting an adenosine-mediated \u201cdon\u2019t eat me signal\u201d augments anti-lymphoma immunity by anti-CD20 monoclonal antibody","volume":"34","author":"Nakamura","year":"2020","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-135941","article-title":"ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136607","article-title":"Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study","volume":"136","author":"Patel","year":"2020","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer Neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma","volume":"29","author":"Schuster","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jha2.116","article-title":"Genetic aberrations of NLRC5 are associated with downregulated MHC-I antigen presentation and impaired T-cell immunity in follicular lymphoma","volume":"1","author":"Gunawardana","year":"2020","journal-title":"eJHaem"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1073\/pnas.1514944112","article-title":"Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens","volume":"112","author":"Young","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","article-title":"B-cell lymphomas present immunoglobulin neoantigens","volume":"133","author":"Khodadoust","year":"2019","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-135954","article-title":"Neoantigens Are Typically Associated with Intact HLA Class I Presentation in Early-Stage Follicular Lymphoma","volume":"136","author":"Tsang","year":"2020","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2019-129391","article-title":"Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience","volume":"134","author":"Parrondo","year":"2019","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/ajh.26016","article-title":"Risk-adapted therapy in follicular lymphoma: Is it time to \u201cFLEX\u201d?","volume":"95","author":"Tobin","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/bloodadvances.2019000458","article-title":"Outcomes of stage I\/II follicular lymphoma in the PET era: An international study from the Australian Lymphoma Alliance","volume":"3","author":"Tobin","year":"2019","journal-title":"Blood Adv."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/2\/152\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:27:57Z","timestamp":1760160477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/2\/152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":142,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["jpm11020152"],"URL":"https:\/\/doi.org\/10.3390\/jpm11020152","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]}}}